Conexeu investor reports 9.99% passive stake

An institutional investor reports beneficial ownership of up to 9.99% of Conexeu Sciences Inc. common shares, including warrant holdings subject to an ownership cap.

Rhea-AI Filing Summary

Conexeu Sciences Inc. (CNXU) has a significant shareholder reported on a Schedule 13G. Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund is disclosed as beneficially owning 4,400,305 common shares, including 2,200,000 common share warrants. The filing states this represents ownership of up to 9.99% of the outstanding common shares. The fund reports sole voting and dispositive power over all of these securities, subject to a 9.99% beneficial ownership limitation that restricts warrant exercises above that level.

Key Figures

Beneficially owned common shares: 4,400,305 shares Common share warrants included: 2,200,000 warrants Percent of class: 9.99% +2 more

5 metrics

Beneficially owned common shares 4,400,305 shares Common shares of Conexeu Sciences Inc. beneficially owned by the reporting person

Common share warrants included 2,200,000 warrants Warrants counted within the beneficial ownership, subject to a 9.99% cap

Percent of class 9.99% Percentage of Conexeu Sciences Inc. common shares beneficially owned

Sole voting power 4,400,305 shares Shares over which the reporting person has sole power to vote

Sole dispositive power 4,400,305 shares Shares over which the reporting person has sole power to dispose

Key Terms

beneficially owned, dispositive power, warrants, Percent of class

4 terms

beneficially owned financial

"Amount beneficially owned: 4,400,305 Includes 2,200,000 common shares warrants"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 4,400,305"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

warrants financial

"Includes 2,200,000 common shares warrants which may not be exercised"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Percent of class financial

"Percent of class: Up to 9.99%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

Who is the major shareholder disclosed in CNXU’s Schedule 13G?

The filing lists Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund as the reporting person, an investor organized in Liechtenstein, with beneficial ownership in Conexeu Sciences Inc. common shares.

How many CNXU common shares does the reporting person beneficially own?

The reporting person beneficially owns 4,400,305 common shares of Conexeu Sciences Inc., which includes common shares issuable upon exercise of certain warrants, subject to a stated beneficial ownership cap.

What percentage of Conexeu Sciences Inc. (CNXU) does this 13G report?

The Schedule 13G states that the reporting person owns up to 9.99% of the class of Conexeu Sciences Inc. common shares, reflecting a beneficial ownership limitation tied to its warrant holdings.

How many CNXU warrants are included in the reported beneficial ownership?

The reported beneficial ownership includes 2,200,000 common share warrants. These warrants may not be exercised if such exercise would cause the reporting person to hold more than 9.99% of Conexeu’s outstanding common shares on the exercise date.

Does the reporting person have sole or shared voting power over CNXU shares?

The reporting person reports sole voting power over 4,400,305 shares and shared voting power over 0 shares, and similarly sole dispositive power over the same amount, with no shared dispositive power.

Who signed the Schedule 13G for Conexeu Sciences Inc.?

The Schedule 13G is signed by Robert Sven Soro, identified with the title Director, on behalf of the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 11:50 AM Accepted by SEC EDGAR 09/04/2026 - 11:49 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Conexeu Sciences Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

20715F100

(CUSIP Number)

05/21/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 20715F100

1

Names of Reporting Persons

Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LIECHTENSTEIN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,400,305.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,400,305.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,400,305.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Includes 2,200,000 common shares warrants which may not be exercised by the Reporting Person if such exercise would result in the Reporting Person holding over 9.99% of the Issuer's outstanding common shares on the date of exercise.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Conexeu Sciences Inc.
(b)	Address of issuer's principal executive offices: 50 West Liberty Street, Sutie 880, Reno, NV 89501
Item 2.
(a)	Name of person filing: Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund ("Reporting Person")
(b)	Address or principal business office or, if none, residence: c/o VP Fund Solutions (Liechtenstein) AG Aeulestrasse 6 Vaduz 9490 Principal of Liechtenstein
(c)	Citizenship: Liechtenstein
(d)	Title of class of securities: Common Shares
(e)	CUSIP Number(s): 20715F100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,400,305 Includes 2,200,000 common shares warrants which may not be exercised by the Reporting Person if such exercise would result in the Reporting Person holding over 9.99% of the Issuer's outstanding common shares on the date of exercise.
(b)	Percent of class: Up to 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,400,305
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,400,305
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund

Signature:	/s/ Robert Sven Soro
Name/Title:	Director
Date:	09/04/2026